The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations, with an outstanding record of achievement dating back more than 100 years. They provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, they are world leaders in discovering new-targeted cancer drugs, identifying new cancer genes and developing new forms of precision radiotherapy.
As part of a programme of expansion of the Division of Structural Biology, The Institute of Cancer Research is seeking to establish three new research teams at the Institute’s Chester Beatty Laboratories in Chelsea, Central London. They are interested in established investigators, for whom permanent Faculty positions are available, and in emerging researchers able to attract externally-funded Personal Fellowships, for whom they will provide mentoring, and a generous support package and transparent review process.
Reflecting the Institute’s mission, they are looking for researchers whose interests inform our understanding of the origins, development and treatment of cancer. Current areas of interest include signal transduction, genome stability, transcription regulation, RNA processing, molecular chaperones, targeted protein degradation, and structure-based drug design.
The Division is exceptionally well equipped for modern structural biology, with excellent managed facilities for protein production, biophysical analysis, crystallisation and X-ray diffraction, and computation, as well as Techni T12 and F20 cryo-electron microscopes, and a state-of the-art FEI Glacios/Falcon 3. The Division also has a 30% share of a Krios/K3 cryoEM facility at the Crick Institute, and rolling allocations of cryoEM time at the eBIC national facility, and X-ray diffraction time at the Diamond, ESRF and Soleil synchrotrons.
For more information and to apply, click here.
